Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

1-41-66 (USA)

The conference call (Call ID 204, followed by the #) will be available for play-back for 48 hours after the call by dialling:
+41-(0)91-612-43-30 (Europe)

+44-(0)207-108-62-33 (UK)

+1-(1)866-416-25-58 (USA)

About Arpida Ltd. Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007.

In June 2007, Arpida announced that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed four Phase I trials. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 New ... Imperial Innovations, Cambridge Innovation Capital and Johnson & ... cancer genomics company focused on harnessing the potential ... cancer testing and treatment, today announced it has ... Imperial Innovations and including Cambridge Innovation Capital and ...
(Date:9/22/2014)... and SANTA CLARA, Calif. , ... WBMD ), the leading source of health ... WebMD/Medscape survey that provide novel insights regarding physician ... diagnosis and care.  Dr. Eric Topol , a ... medicine, who serves as both Editor-in-Chief of Medscape and ...
(Date:9/22/2014)... cell fragments whose job it is to stop bleeding, ... But they can "feel" the physical environment around them, ... Platelets respond to surfaces with greater stiffness by increasing ... other platelets and other components of the clotting system, ... give them credit for, in that they are able ...
(Date:9/22/2014)... University of Minnesota electrical engineering researchers have developed ... time demonstrates mechanical transportation of light. The discovery ... more efficient optical devices for computation and communication. ... electrical and computer engineering assistant professor Mo Li ... published online and will appear in the October ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4Platelets modulate clotting behavior by 'feeling' their surroundings 2Engineers show light can play seesaw at the nanoscale 2
... KENILWORTH and WHITEHOUSE STATION, N.J., April 25 ,Schering-Plough/MERCK ... letter from the U.S. Food and Drug Administration,(FDA) ... montelukast for,the treatment of allergic rhinitis symptoms in ... New Drug Application filing for loratadine/montelukast was accepted,by ...
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) announced today that it ... that the Company is not in,compliance with the $1.00 ... Global Market pursuant to Marketplace Rule 4450,(a)(5). This notification, ... is a standard communication when the bid price of ...
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... the consumer and professional markets, announced,today that it ... Conference being held April 30 - May 2, ... Zwanziger, Chief Executive Officer, will,attend. His presentation is ...
Cached Biology Technology:Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 2Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 3Keryx Biopharmaceuticals Receives Nasdaq Notification 2Keryx Biopharmaceuticals Receives Nasdaq Notification 3
(Date:9/23/2014)... Company has secured $21 million in a Series C ... the Company,s cancer immunotherapy pipeline and advance its lead ... the round, with participation from Majuven and all existing ... Harbinger Venture Capital. , Eureka is engaged in ... mimic the functions of a T cell receptor, a ...
(Date:9/23/2014)... of scientists has identified a gene mutation that ... which the bone marrow fails to produce normal ... which three generations had blood disorders, the researchers ... telomeres, chromosomal structures with crucial roles in normal ... help suggest future molecular-based treatments that bypass the ...
(Date:9/23/2014)... the development of animals and plants. The central problem ... translated in a reliable manner to give specific spatial ... of stripe formation is a classic paradigm in developmental ... the French flag, is caused by a gradient of ... low concentrations of the morphogen a "blue", "white" or ...
Breaking Biology News(10 mins):Gene mutation discovered in blood disorder 2Recreating the stripe patterns found in animals by engineering synthetic gene networks 2
... the cacao genome is complete, a consortium of academic, ... scientists performed much of the sequencing work, which is ... website of the Cacao Genome Database project. Despite ... Inc., Cacao Genome Database scientists say one of their ...
... , BOSTON (9-15-10) -- A team led by Boston ... four-year grant from the National Institutes of Health to ... could lead to individual genome sequencing for less than ... on an initial, $2.2 million NIH grant and led ...
... 15 September 2010 -- The European Society for Medical Oncology ... the advancement of medical research. The awards will be presented ... 35th ESMO Congress, to take place from 8-12 October in ... the 2010 ESMO Award for his key role in the ...
Cached Biology News:Chocolate farmers could benefit from newly sequenced cacao genome 2Chocolate farmers could benefit from newly sequenced cacao genome 3Chocolate farmers could benefit from newly sequenced cacao genome 4BU team wins $4.1M genome grant 2Top cancer specialists receive ESMO awards 2Top cancer specialists receive ESMO awards 3Top cancer specialists receive ESMO awards 4
... synthetic peptide whose sequence is from the C-terminal end of the mouse ... from amino acids 429 to 448 of RAR*. The sequence of ... V - S - P - S - S - V - ... Q - S - P - L - L - Q ...
... The ELx50 is a fast and ... equipped with our patented Dual-ActionTM 16-channel manifold. ... of the dispense and aspiration manifolds for ... 96- and 384-well formats. The problem of ...
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
... 1200L sets the new standard for ... incorporating the latest technologies and providing ... analytical needs. The Atmospheric Pressure ... Quadrupole Analyzer provide superior selectivity and ...
Biology Products: